Literature DB >> 11319653

Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance.

D Hansen1, A Astrup, S Toubro, N Finer, P Kopelman, J Hilsted, S Rössner, W Saris, L Van Gaal, W James, M Goulder.   

Abstract

BACKGROUND: In this report we assess pre-treatment determinants of weight loss and maintenance outcome in The Sibutramine Trial of Obesity Reduction and Maintenance (STORM), a 2 y randomized, double-blind, placebo-controlled, European multicenter study examining the effect of sibutramine (Sib) on inducing and maintaining weight loss in obese subjects. MATERIAL: A total of 605 obese patients (BMI: 30-45 kg/m2) of both gender were included from eight European centers and treated for 24 months. The patients were treated for the initial 6 months by Sib (10 mg/day) and a low-fat low-energy, individualized diet (600 kcal/day deficit). The 467 patients who achieved >5% weight loss after 6 months were randomized 3∶1 to Sib (10 mg/day) (Sib/Sib) and placebo (Sib/Pla) for weight maintenance over a further 18 months. MAIN OUTCOME AND ANALYSES: Pre-treatment individual characteristics were assessed as predictors of 6 months weight loss (kg) and 24 months weight maintenance using simple and multivariate correlation and regression analyses.
RESULTS: In univariate analyses, the 6 month weight loss (n=505) was positively associated with pre-treatment body weight (r=0.27), height (r=0.18), fat-free mass (r=0.21) (all P<0.001), fat mass (r=0.13, P<0.03), and resting metabolic rate (r=0.13, P<0.003). However, no relation was found with age, gender, smoking status, age at onset of obesity, or number of previous slimming attempts. The same predictors were found for weight change to endpoint in the Sib/Sib group (n=350), while no predictors were identified in the Sib/Pla (n=114). In the multivariate regression analysis only pre-treatment body weight predicted weight loss at 6 months (P<0.001). Weight change (kg) to 24 month was predicted by: 4.34+0.07*body weight (kg)-4*treatment (Sib=1, Pla=0)-0.06*age (y), (r2=8%, P<0.001).
CONCLUSION: Only pre-treatment body weight seems to be an important independent predictor of 6 months weight loss and 24 month weight maintenance in this study on diet and Sib. As only 8% of the variation in 24 months weight change could be explained by the predictors, the clinical value of this information is limited.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11319653     DOI: 10.1038/sj.ijo.0801481

Source DB:  PubMed          Journal:  Int J Obes Relat Metab Disord


  21 in total

1.  Sibutramine and the sympathetic nervous system in obese humans.

Authors:  William G Haynes; Zoltan Egri
Journal:  Clin Auton Res       Date:  2005-06       Impact factor: 4.435

Review 2.  Drug interventions for the treatment of obesity in children and adolescents.

Authors:  Emma Mead; Greg Atkinson; Bernd Richter; Maria-Inti Metzendorf; Louise Baur; Nicholas Finer; Eva Corpeleijn; Claire O'Malley; Louisa J Ells
Journal:  Cochrane Database Syst Rev       Date:  2016-11-29

3.  Very low calorie diet (VLCD) followed by a randomized trial of corset treatment for obesity in primary care.

Authors:  Ingrid Wikstrand; Jarl Torgerson; Kristina Bengtsson Boström
Journal:  Scand J Prim Health Care       Date:  2010-06       Impact factor: 2.581

4.  Do women with pelvic floor dysfunction referred by gynaecologists and urologists at hospitals complete a pelvic floor muscle training programme? A retrospective study, 1992-2008.

Authors:  Sigrid Tibaek; Christian Dehlendorff
Journal:  Int Urogynecol J       Date:  2013-01-05       Impact factor: 2.894

5.  Readiness redefined: a behavioral task during screening predicted 1-year weight loss in the look AHEAD study.

Authors:  Adam G Tsai; Anthony N Fabricatore; Thomas A Wadden; Allison J Higginbotham; Andrea Anderson; John Foreyt; James O Hill; Robert W Jeffery; Marci E Gluck; Edward W Lipkin; Rebecca S Reeves; Brent Van Dorsten
Journal:  Obesity (Silver Spring)       Date:  2013-12-09       Impact factor: 5.002

Review 6.  Sibutramine lost and found.

Authors:  O Bosello; M O Carruba; E Ferrannini; C M Rotella
Journal:  Eat Weight Disord       Date:  2002-09       Impact factor: 4.652

Review 7.  Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.

Authors:  S L Norris; X Zhang; A Avenell; E Gregg; C H Schmid; J Lau
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

8.  Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy.

Authors:  Andres Acosta; Michael Camilleri; Andrea Shin; Maria I Vazquez-Roque; Johanna Iturrino; Duane Burton; Jessica O'Neill; Deborah Eckert; Alan R Zinsmeister
Journal:  Gastroenterology       Date:  2014-12-06       Impact factor: 22.682

9.  Effects of sibutramine and rimonabant in rats trained to discriminate between 22- and 2-h food deprivation.

Authors:  David C Jewett; Thomas W Hahn; Travis R Smith; Britta L Fiksdal; Jason M Wiebelhaus; Andrew R Dunbar; Catherine R Filtz; Noah L Novinska; Allen S Levine
Journal:  Psychopharmacology (Berl)       Date:  2008-10-15       Impact factor: 4.530

10.  Taking Orlistat: Predicting Weight Loss over 6 Months.

Authors:  Amelia Hollywood; Jane Ogden
Journal:  J Obes       Date:  2010-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.